International Liver Cancer Association Annual Conference | Conference

High Interferon Signaling and Antigen Presentation Predicts for Response Only in Frontline Advanced HCC

September 5th 2021

Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.

Dr. Vogel on the Utility of Frontline Lenvatinib or Sorafenib in HCC

September 4th 2021

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Dr. Singal on the Results of a Mailed Outreach Strategy for Surveillance Utilization in HCC

September 4th 2021

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Dr. Rich on the Prevalence of Cachexia in HCC

September 4th 2021

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

Dual Checkpoint Blockade/Ablation Regimens Show Intriguing Activity in Advanced HCC

September 4th 2021

Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.

Predictive Biomarkers for Checkpoint Inhibition Remain Unmet Need in HCC

September 3rd 2021

Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.

Dr. Cheng on the Need For Biomarkers in HCC

September 28th 2018

Ann-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.

Dr. Basu on Second-Line Therapy in HCC

September 28th 2018

Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discussed second-line therapy for patients with hepatocellular carcinoma.

Dr. Llovet on Combination Therapy in HCC

September 26th 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.

Dr. Villanueva on Challenges For Liquid Biopsies in HCC

September 25th 2018

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses remaining challenges with liquid biopsies in hepatocellular carcinoma.

Dr. Primrose on Adjuvant Capecitabine For Biliary Tract Cancer

September 21st 2018

John Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.

Immunotherapy Combos May Shape the Future of HCC Therapy

September 17th 2018

The development of novel immunotherapy combinations is among the most significant trends emerging as part of the next wave of discovery in hepatocellular carcinoma, with several promising regimens incorporating checkpoint inhibitors undergoing testing in phase III studies.

Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib

September 16th 2018

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.

Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm

September 16th 2018

Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.

Dr. Lencioni on Assessing Response to HCC Therapy

September 16th 2018

Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.

Sangro Says Immunotherapy May Be the Future of HCC Treatment

September 16th 2018

Bruno Sangro, MD, discussed the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for patients with hepatocellular carcinoma.

Regorafenib Sustains OS Benefit in RESORCE Trial Update

September 16th 2018

Regorafenib maintained a prolonged overall survival benefit as second-line therapy for patients with advanced hepatocellular carcinoma in a 2-year updated analysis of key findings from the pivotal RESORCE trial.

Independent Review Backs Key REFLECT Findings With Lenvatinib in HCC

September 16th 2018

The positive outcomes that lenvatinib demonstrated as first-line therapy for patients with hepatocellular carcinoma are confirmed in an independent assessment conducted as part of the pivotal, international phase III REFLECT trial.

Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials

September 15th 2018

Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.

Dr. Abou-Alfa on Key Trends in HCC Research

September 15th 2018

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, describes what he sees as key areas of research into the treatment of hepatocellular carcinoma as therapy moves beyond existing drugs and into novel approaches.